CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
16 results
Search Results
Now showing 1 - 10 of 16
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Early prediction of functional mobility severity after stroke: two key milestones(2024) ;Patricia Vargas ;Marcos Maldonado-DiazTania Gutiérrez-PanchanaScopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Sport COVID-19 Orientations: Recommendations for return to physical activity and sports in children and adolescents(2020) ;RAUL ANDRES SMITH PLAZA ;Kalazich Rosalesa, Cesar ;Valderrama Erazob, Paulo ;Flandez Valderrama, JorgeBurboa Gonzalez, Jair4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Scrub typhus in Tierra del Fuego: a tropical rickettsiosis in a subantarctic region(2021); ; ;Constanza Martínez-Valdebenito ;Gerardo Acosta-JamettKatia Abarca10Scopus© Citations 10 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Atovaquone/Proguanil Resistance in an Imported Malaria Case in Chile(2021) ;Stella M. Chenet ;Alan Oyarce ;Jorge Fernandez ;Rafael Tapia-Limonchi<jats:title>ABSTRACT</jats:title><jats:p>In November 2018, we diagnosed a cluster of falciparum malaria cases in three Chilean travelers returning from Nigeria. Two patients were treated with sequential intravenous artesunate plus oral atovaquone/proguanil (AP) and one with oral AP. The third patient, a 23-year-old man, presented with fever on day 29 after oral AP treatment and was diagnosed with recrudescent falciparum malaria. The patient was then treated with oral mefloquine, followed by clinical recovery and resolution of parasitemia. Analysis of day 0 and follow-up blood samples, collected on days 9, 29, 34, 64, and 83, revealed that parasitemia had initially decreased but then increased on day 29. Sequencing confirmed Tyr268Cys mutation in the <jats:italic>cytochrome b</jats:italic> gene, associated with atovaquone resistance, in isolates collected on days 29 and 34 and <jats:italic>P. falciparum dihydrofolate reductase</jats:italic> mutation Asn51Ile, associated with proguanil resistance in all successfully sequenced samples. Molecular characterization of imported malaria contributes to clinical management in non-endemic countries, helps ascertain the appropriateness of antimalarial treatment policies, and contributes to the reporting of drug resistance patterns from endemic regions.</jats:p>4Scopus© Citations 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 20Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Funcionalidad de prótesis de mano impresa en 3D en adolescentes con amputación congénita parcial de mano: una serie de casos(2020) ;Jacqueline Dote ;Paula Nahuelhual ;Rodrigo Cubillos ;Gabriel FuentesJorge Zuñiga<jats:p>Objetivo: Describir el efecto de la prótesis impresa en 3D Cyborg Beast en la funcionalidad de miembros superiores (MMSS) en adolescentes con amputación congénita parcial de mano.Casos Clínicos: Se seleccionaron 5 pacientes entre 12 y 17 años con amputación congénita parcial de mano en el Instituto Teletón Santiago. Los pacientes fueron entrenados en el uso de la prótesis por 4 sesiones. Se evaluó la función basal (sin prótesis), al mes y los 4 meses de uso de la prótesis con la pauta Bilan 400 points modificada y la percepción de funcionalidad de MMSS sin y con prótesis con la “Upper Extremity Function Index (UEFI)”. Al mes y 4 meses de uso, el porcentaje de cambio para funcionalidad de mano fue de -11% y -4% para la extremidad no afectada y de -9% y -2% para la afectada. El porcentaje de cambio para la percepción de funcionalidad de MMSS fue de -62%.Conclusiones: El uso de la prótesis de mano Cyborg Beast no fue una solución funcional para los 5 pacientes incluidos en este estudio. Futuras investigaciones son necesarias para poder mejorar la funcionalidad de estos diseños de prótesis impresa en tecnología 3D.</jats:p>Scopus© Citations 4 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Oxygen desaturation and adverse outcomes in acute stroke: Secondary analysis of the HeadPoST study(2021) ;Menglu Ouyang ;Christine Roffe ;Laurent Billot ;Lili SongXia Wang1Scopus© Citations 2 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Influence of Including Patients with Premorbid Disability in Acute Stroke Trials: The HeadPoST Experience(2021) ;Xia Wang ;Tom J. Moullaali ;Menglu Ouyang ;Laurent BillotElse Charlotte Sandset<jats:p><b><i>Background:</i></b> Patients with premorbid functional impairment are generally excluded from acute stroke trials. We aimed to determine the impact of including such patients in the Head Positioning in acute Stroke Trial (HeadPoST) and early additional impairment on outcomes. <b><i>Methods:</i></b> Post hoc analyses of HeadPoST, an international, cluster-randomized crossover trial of lying-flat versus sitting-up head positioning in acute stroke. Associations of early additional impairment, defined as change in modified Rankin scale (mRS) scores from premorbid levels (estimated at baseline) to Day 7 (“early ΔmRS”), and poor outcome (mRS score 3–6) at Day 90 were determined with generalized linear mixed model. Heterogeneity of the trial treatment effect was tested according to premorbid mRS scores 0–1 versus 2–5. <b><i>Results:</i></b> Of 8,285 patients (38.9% female, mean age 68 ± 13 years) with complete data, there were 1,984 (23.9%) with premorbid functional impairment (mRS 2–5). A significant linear association was evident for early ∆mRS and poor outcome (per 1-point increase in ΔmRS, adjusted odds ratio 1.20, 95% confidence interval 1.14–1.27; <i>p</i> &#x3c; 0.0001). Patients with greater premorbid functional impairment were less likely to develop additional impairment, but their risk of poor 90-day outcome significantly increased with increasing (worse) premorbid mRS scores (linear trend <i>p</i> &#x3c; 0.0001). There was no heterogeneity of the trial treatment effect by level of premorbid function. <b><i>Conclusions:</i></b> Early poststroke functional impairment that exceeded premorbid levels was associated with worse 90-day outcome, and this association increased with greater premorbid functional impairment. Yet, including premorbid impaired patients in the HeadPoST did not materially affect the subsequent treatment effect. <b><i>Clinical Trial Registration:</i></b> HeadPoST is registered at http://www.ClinicalTrials.gov (NCT02162017). </jats:p>1Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 5Scopus© Citations 6 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 36Scopus© Citations 2